Corrigendum: CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses (Nature (2017) 543 (564-567) DOI: 10.1038/nature21710);CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses

Nature

Volumn 543, Issue 7646, 2017, Pages 564-567

  Descours, Benjamin ^a   Petitjean, Gaël ^a   López Zaragoza, José Luis ^b,c,d   Bruel, Timothée ^b,e   Raffel, Raoul ^a   Psomas, Christina ^f   Reynes, Jacques ^f   Lacabaratz, Christine ^b,c,d   Levy, Yves ^b,c,d   Schwartz, Olivier ^b,e   Lelievre, Jean Daniel ^b,c,d   Benkirane, Monsef ^a  

^a UNIV MONTPELLIER   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c INSERM U955   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e CNRS   (France)

^f MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FC RECEPTOR IIA; IMMUNOGLOBULIN FC FRAGMENT; MEMBRANE PROTEIN; T LYMPHOCYTE RECEPTOR; VIRUS DNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FC RECEPTOR;

CELLS AND CELL COMPONENTS; EXPERIMENTAL STUDY; GENE; GENE EXPRESSION; GENETIC MARKER; HUMAN IMMUNODEFICIENCY VIRUS; LABORATORY METHOD; PERSISTENCE; PROTEIN; SUBPOPULATION;

ANTIGEN EXPRESSION; ANTIRETROVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; BYSTANDER EFFECT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE CARRIER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; T LYMPHOCYTE SUBPOPULATION; BLOOD; CELL CULTURE; CELL DIVISION; CELL SEPARATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEK293 CELL LINE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; UPREGULATION; VIROLOGY; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL SEPARATION; CELLS, CULTURED; DNA, VIRAL; GENE EXPRESSION PROFILING; HEK293 CELLS; HIV INFECTIONS; HIV-1; HUMANS; PROVIRUSES; RECEPTORS, IGG; UP-REGULATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 85016136898     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22807     Document Type: Erratum

References (23)

1. Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 94, 13193-13197 (1997).
2. Chun, T. W., Davey, R. T., Jr, Engel, D., Lane, H. C. & Fauci, A. S. Re-emergence of HIV after stopping therapy. Nature 401, 874-875 (1999).
3. Finzi, D. et al. Identifcation of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
4. Zack, J. A. et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222 (1990).
5. Stevenson, M., Stanwick, T. L., Dempsey, M. P. & Lamonica, C. A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9, 1551-1560 (1990).
6. Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893-900 (2009).
7. Laguette, N. et al. SAMHD1 is the dendritic-and myeloid-cell-specifc HIV-1 restriction factor counteracted by Vpx. Nature 474, 654-657 (2011).
8. + cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection. PLoS Pathog. 7, e1002425 (2011).
9. Hrecka, K. et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474, 658-661 (2011).
10. + T-cells. Retrovirology 9, 87 (2012).
11. + T cells. Nat. Med. 18, 1682-1687 (2012).
12. Cribier, A., Descours, B., Valadão, A. L., Laguette, N. & Benkirane, M. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell Reports 3, 1036-1043 (2013).
13. Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47 (2008).
14. Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H. & Lambrecht, B. N. The function of Fcγ receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 14, 94-108 (2014).
15. Laird, G. M. et al. Rapid quantifcation of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 9, e1003398 (2013).
16. Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540-551 (2013).
17. Cohn, L. B. et al. HIV-1 integration landscape during latent and active infection. Cell 160, 420-432 (2015).
18. Bournazos, S. et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158, 1243-1253 (2014).
19. Bruel, T. et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat. Commun. 7, 10844 (2016).
20. Horwitz, J. A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl Acad. Sci. USA 110, 16538-16543 (2013).
21. Avettand-Fènoël, V. et al. LT R real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J. Med. Virol. 81, 217-223 (2009).
22. Pereira Bittencourt Passaes, C. et al. Ultrasensitive HIV-1 p24 detects single infected cells and diferences in reservoir induction by latency-reversal agents. J. Virol. 91, e.02296-16 (2017).
23. Rosenbloom, D. I. et al. Designing and interpreting limiting dilution assays: general principles and applications to the latent reservoir for Human Immunodefciency Virus-1. Open Forum Infect. Dis. 2, ofv123 (2015).